Clinical trial
Le Traitement Par Lenvatinib + Anti-PD1 Du Mélanome Métastatique
NCT06586580 is registered in ClinicalTrials.gov with Centre Hospitalier Universitaire de Besancon as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Le Traitement Par Lenvatinib + Anti-PD1 Du Mélanome Métastatique
- Lead sponsor
- Centre Hospitalier Universitaire de Besancon
- Phase
- Observational
- Overall status
- Completed
- Start date
- March 30, 2023
- Completion date
- December 31, 2023
- Enrollment
- 18 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
metastatic melanoma